|
Volumn 6, Issue 8, 2002, Pages 649-650
|
Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
TUBERCULOSTATIC AGENT;
BACTERIAL VIRULENCE;
COST BENEFIT ANALYSIS;
DECISION MAKING;
DRUG EFFICACY;
HEALTH CARE COST;
HEALTH CARE POLICY;
MULTIDRUG RESISTANCE;
MYCOBACTERIUM TUBERCULOSIS;
PRIORITY JOURNAL;
SHORT SURVEY;
TUBERCULOSIS;
TUBERCULOSIS CONTROL;
ARTICLE;
COST;
ECONOMICS;
HUMAN;
INFECTION CONTROL;
ANTITUBERCULAR AGENTS;
COMMUNICABLE DISEASE CONTROL;
COST-BENEFIT ANALYSIS;
COSTS AND COST ANALYSIS;
HUMAN;
TUBERCULOSIS, MULTIDRUG-RESISTANT;
HUMANS;
|
EID: 0035992351
PISSN: 10273719
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
Times cited : (12)
|
References (11)
|